Last updated: August 11, 2026
ACTIQ, the brand name for oral transmucosal fentanyl citrate, moved from a high-value specialty opioid to a mature, heavily restricted product with limited publicly disclosed commercial relevance. Its historical revenue depended on treatment of breakthrough cancer pain in opioid-tolerant patients. Sales declined as generic fentanyl products entered, opioid-safety controls expanded, prescriber access narrowed, and payers reduced coverage. Teva Pharmaceuticals acquired ACTIQ through its 2011 purchase of Cephalon, but Teva does not report ACTIQ as a separate material revenue line in current filings.[1]
What is ACTIQ and which patients does it treat?
ACTIQ is a fentanyl citrate lozenge attached to a plastic applicator. The product delivers fentanyl through the oral mucosa and is indicated for breakthrough cancer pain in patients who are already receiving and tolerant to around-the-clock opioid therapy.[2]
The product is not approved for routine acute pain, postoperative pain, migraine, or opioid-naive patients. Its approved use is narrow because fentanyl can cause fatal respiratory depression, particularly when used outside the labeled population.
ACTIQ dosage and delivery system
ACTIQ is supplied in multiple strengths, historically ranging from 200 micrograms to 1,600 micrograms. The patient places the lozenge between the cheek and gum and moves it around the mouth over approximately 15 minutes. The applicator is then discarded.
The delivery format differentiated ACTIQ from conventional oral opioids. It also created commercial barriers:
- The product required patient education and controlled dispensing.
- Prescribers had to understand opioid tolerance requirements.
- The product was subject to special risk-management controls.
- Accidental ingestion posed a high risk to children and opioid-naive adults.
- The dosage form was difficult to substitute directly with ordinary fentanyl tablets or patches.
How did ACTIQ generate revenue?
ACTIQ generated premium specialty-pharmaceutical revenue through a patented transmucosal delivery system and a restricted oncology indication. Historical sales were materially higher than the product’s current reported contribution.
Cephalon’s public filings identified ACTIQ as one of its major commercial products before Teva acquired the company. ACTIQ annual sales were approximately $350 million in the late 2000s, based on Cephalon’s product-level reporting.[3] Sales later contracted as generic competition, regulatory restrictions, and opioid-market scrutiny increased.
| Period |
Commercial position |
Financial implication |
| Late 1990s |
ACTIQ launched for breakthrough cancer pain |
Premium specialty product with limited direct competition |
| Early 2000s |
Expansion through oncology and pain specialists |
Rapid revenue growth and strong product concentration |
| Mid-to-late 2000s |
Mature branded product |
Annual sales reached roughly $350 million |
| 2008 onward |
Generic fentanyl competition developed |
Price and volume pressure increased |
| 2011 |
Teva acquired Cephalon |
ACTIQ became part of Teva’s specialty and generic portfolio |
| 2012 onward |
TIRF REMS and opioid controls expanded |
Prescriber and dispensing friction increased |
| 2020s |
Mature, restricted product |
Standalone ACTIQ revenue is not separately disclosed |
ACTIQ’s financial profile changed from growth asset to portfolio maintenance product. The commercial value shifted from brand expansion to residual cash generation, manufacturing continuity, and management of regulatory obligations.
When did ACTIQ lose exclusivity?
ACTIQ’s primary commercial exclusivity eroded in the late 2000s as generic oral transmucosal fentanyl products reached the U.S. market. The exact economic loss of exclusivity occurred through a combination of patent expiry, generic approvals, and reduced differentiation rather than through a single publicly reported event.
The original ACTIQ patent estate protected the product’s oral transmucosal delivery approach, formulation, and use. Key intellectual-property protection was associated with Cephalon and predecessor companies, including patents covering fentanyl delivery through a solid oral dosage form. Many of the earliest patents reached the end of their ordinary U.S. terms during the 2000s.
What patents protected ACTIQ?
ACTIQ protection historically included several layers:
- Composition and formulation claims covering fentanyl citrate in a solid oral dosage form.
- Oral transmucosal delivery claims covering absorption through the mouth.
- Applicator and product-design claims.
- Method-of-use claims for breakthrough cancer pain.
- Manufacturing and dosage-control claims.
Patent protection was commercially important because conventional fentanyl products did not provide an automatic therapeutic substitute for ACTIQ. Once formulation and delivery claims expired or became vulnerable to invalidity and non-infringement arguments, generic manufacturers could compete through abbreviated new drug applications.
The current commercial question is less whether ACTIQ has an enforceable blocking patent than whether any remaining formulation, manufacturing, or regulatory barrier can prevent substitution. Teva’s public filings do not identify ACTIQ as a current major patent-protected growth product.[1]
What is the Orange Book status of ACTIQ?
ACTIQ was approved under FDA New Drug Application 20-747. FDA labeling identifies oral transmucosal fentanyl citrate as the active ingredient and limits use to opioid-tolerant adults with breakthrough cancer pain.[2]
The Orange Book historically listed ACTIQ-related patents and generic-drug certifications. As core patents expired, the product’s protection shifted from patent exclusivity to regulatory controls and market complexity. Orange Book listings should be reviewed by NDA and dosage strength because patent status can differ between the reference product and individual generic applications.[4]
What exclusivity did ACTIQ receive?
ACTIQ received ordinary small-molecule regulatory exclusivity associated with its original approval and subsequent labeling activity. Its commercial protection did not depend on biologic exclusivity, pediatric exclusivity, or orphan-drug exclusivity in the same way as a rare-disease biologic.
The product’s most important protection was market-specific: physicians had limited alternatives for rapid transmucosal fentanyl delivery in opioid-tolerant cancer patients. That advantage weakened after generic oral transmucosal fentanyl products became available.
Which companies challenged ACTIQ patents?
Generic competition involved companies operating in the abbreviated new drug application market for fentanyl citrate oral transmucosal products. Generic manufacturers and Teva’s own generic operations were positioned to compete with the reference product after the main patent barriers weakened.
The available public record does not support treating ACTIQ as an active, large-scale Paragraph IV litigation franchise in the 2020s. The principal commercial challenge occurred during the earlier genericization cycle, when generic manufacturers contested or designed around the remaining ACTIQ patent estate.
What Paragraph IV risks affected ACTIQ?
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. For ACTIQ, this pathway created the standard risks associated with generic oral transmucosal fentanyl:
- Accelerated price erosion after the first approved generic.
- Potential 30-month litigation stays.
- Loss of branded market share before patent expiry.
- Product-specific substitution disputes.
- Litigation over delivery-system and dosage-form claims.
The relevant risk was not only legal entry. Generic entry also reduced the brand’s ability to maintain premium pricing with payers and specialty pharmacies.
How did the TIRF REMS affect ACTIQ sales?
FDA required a Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl, known as the TIRF REMS, because of misuse, abuse, addiction, overdose, and death risks.[5]
The TIRF REMS applied to ACTIQ and other transmucosal immediate-release fentanyl products. It required controls involving prescriber education, patient enrollment, pharmacy processes, and verification of opioid tolerance.
The program affected ACTIQ economics in four ways:
- It reduced the pool of eligible prescribers.
- It increased dispensing and administrative costs.
- It restricted off-label or inappropriate demand.
- It reinforced payer and health-system scrutiny.
The REMS was commercially protective in one sense because it limited indiscriminate substitution into broader pain markets. It was commercially negative because it reduced prescription volume and increased operating friction.
What regulatory actions changed ACTIQ’s market?
ACTIQ’s market was constrained by a series of FDA and public-health measures directed at high-risk opioids. The most important restrictions involved opioid tolerance, fentanyl safety, abuse prevention, and controlled dispensing.
FDA labeling requires that patients be opioid tolerant before receiving ACTIQ. The product label defines opioid tolerance through minimum daily exposure to another opioid for at least one week.[2] This requirement prevents ACTIQ from competing broadly in ordinary analgesia.
The FDA also issued safety communications addressing accidental exposure to fentanyl products, including serious risks to children and opioid-naive individuals.[6] These communications increased the compliance burden for manufacturers, pharmacies, hospitals, and caregivers.
What is ACTIQ’s current financial trajectory?
ACTIQ is a declining or mature product rather than a disclosed growth driver for Teva. Teva’s current reporting aggregates products across broad business segments and does not provide a standalone ACTIQ revenue series.[1]
The financial trajectory can be summarized as follows:
| Driver |
Historical effect |
Current effect |
| Specialty oncology positioning |
Supported premium pricing |
Remains narrow and volume-limited |
| Generic entry |
Reduced price and share |
Persistent substitution pressure |
| TIRF REMS |
Increased access friction |
Limits market expansion |
| Opioid scrutiny |
Reduced inappropriate demand |
Raises compliance costs |
| Teva ownership |
Added manufacturing and portfolio scale |
No separate public ACTIQ growth disclosure |
| Limited indication |
Protected clinical niche |
Prevents large-volume expansion |
| Fentanyl supply controls |
Added operational risk |
Can affect availability and inventory costs |
ACTIQ’s residual value depends on supply reliability, contract coverage, the number of active generic competitors, and the continuing need for transmucosal fentanyl in oncology. There is no public basis for valuing ACTIQ as a standalone multibillion-dollar asset or for projecting historical peak sales into the current market.
What generic entry risks exist for ACTIQ?
Generic entry risk remains high because the core product is a small-molecule opioid with an established reference product and a mature regulatory pathway.
The principal risks to branded ACTIQ are:
- Generic price competition.
- Pharmacy-level substitution.
- Payer preference for lower-cost fentanyl products.
- Reduced brand loyalty after loss of patent exclusivity.
- Manufacturing interruptions affecting either the brand or generics.
- Regulatory changes that narrow or expand access to transmucosal fentanyl.
The main offset is that ACTIQ is a specialized dosage form. Generic manufacturers must satisfy requirements for fentanyl content uniformity, transmucosal delivery, stability, dose proportionality, and safe product handling. These requirements create development and manufacturing barriers, but they do not restore the brand’s historical exclusivity.
How does ACTIQ compare with other fentanyl products?
ACTIQ differs materially from transdermal fentanyl, injectable fentanyl, buccal tablets, nasal sprays, and ordinary oral opioids.
| Product type |
Delivery route |
Primary commercial use |
ACTIQ comparison |
| ACTIQ |
Oral transmucosal lozenge |
Breakthrough cancer pain |
Rapid delivery with restricted opioid-tolerant use |
| Fentanyl patch |
Transdermal |
Continuous chronic pain |
Slower, continuous exposure; not a direct substitute |
| Injectable fentanyl |
Intravenous or intramuscular |
Hospital and procedural use |
Different care setting and administration |
| Fentanyl buccal tablet |
Buccal mucosa |
Breakthrough cancer pain |
Similar indication but different dosage form |
| Fentanyl nasal spray |
Intranasal |
Breakthrough cancer pain |
Alternative rapid-delivery route |
| Immediate-release oral opioids |
Gastrointestinal absorption |
Broad acute or chronic pain |
Slower onset and different exposure profile |
ACTIQ’s closest competitive products are other transmucosal immediate-release fentanyl products. Generic products in that category create the greatest direct pricing threat.
What manufacturing and intellectual-property barriers remain?
Manufacturing oral transmucosal fentanyl requires precise control of drug loading and content uniformity. Small deviations can produce clinically significant dosing differences because fentanyl has high potency.
Operational barriers include:
- Controlled-substance security.
- Specialized dosage-form manufacturing.
- Batch testing and content uniformity.
- Restricted distribution procedures.
- Serialization and supply-chain monitoring.
- Compliance with DEA and FDA requirements.
- Safe disposal and patient-use instructions.
These barriers can limit the number of credible manufacturers. They support supply stability for an established producer but do not provide the pricing power associated with active patent exclusivity.
What litigation and settlement agreements affect ACTIQ?
ACTIQ has been affected by the broader opioid litigation environment, including claims involving opioid marketing, distribution, misuse, and public-health costs. Teva has disclosed substantial opioid-related litigation and settlement obligations across its portfolio.[1]
Public filings do not establish a current ACTIQ-specific patent settlement as a principal driver of Teva’s financial outlook. The most material legal exposure is broader opioid litigation and regulatory compliance, not a continuing branded-product patent dispute.
What is the competitive outlook for ACTIQ?
ACTIQ’s competitive outlook is defensive. The product retains a clinically defined role for opioid-tolerant cancer patients who require rapid treatment for breakthrough pain. Its market is constrained by:
- A narrow labeled population.
- Generic alternatives.
- Opioid prescribing controls.
- Payer pressure.
- Safety concerns.
- Limited ability to expand into non-cancer pain.
Growth would require a material change in the product’s access rules, clinical positioning, or competitive environment. Current regulatory policy points toward tighter control rather than broad expansion.
Key Takeaways
- ACTIQ is oral transmucosal fentanyl citrate for breakthrough cancer pain in opioid-tolerant patients.
- Historical annual sales reached approximately $350 million during the Cephalon period.
- Teva acquired ACTIQ through its $6.8 billion acquisition of Cephalon in 2011.
- Core patent and exclusivity protection eroded as generic oral transmucosal fentanyl products entered the market.
- TIRF REMS requirements increased prescribing, dispensing, and compliance friction.
- Teva does not separately disclose current ACTIQ revenue as a material product-level figure.
- The main commercial risks are generic substitution, opioid regulation, payer restrictions, and manufacturing compliance.
- The product remains commercially relevant as a niche oncology analgesic but is not a current high-growth pharmaceutical asset.
FAQs about ACTIQ market and patents
Is ACTIQ still available in the United States?
ACTIQ and generic oral transmucosal fentanyl products have had changing commercial availability by manufacturer, strength, and distribution channel. FDA approval status and actual supply status are separate questions.
Is ACTIQ stronger than oxycodone?
ACTIQ contains fentanyl, a highly potent opioid. Dose comparisons with oxycodone are clinically sensitive and cannot be made by milligram-to-milligram substitution.
Does Teva still own ACTIQ?
Teva obtained ACTIQ through its acquisition of Cephalon. Teva’s current public reports do not identify ACTIQ as a separately reported major revenue product.
Are ACTIQ generics automatically interchangeable?
Approval of a generic does not mean that every fentanyl dosage form is interchangeable in the same manner as every other product. Substitution depends on FDA ratings, product labeling, state law, and pharmacy policy.
Is ACTIQ protected by orphan-drug exclusivity?
ACTIQ’s principal commercial protection came from patents, formulation differentiation, indication restrictions, and specialty distribution controls. Its market position did not depend primarily on current orphan-drug exclusivity.
References
- Teva Pharmaceutical Industries Ltd. (2024). Annual report on Form 20-F for the year ended December 31, 2023.
- U.S. Food and Drug Administration. (2023). ACTIQ prescribing information.
- Cephalon, Inc. (2010). Annual report on Form 10-K for the year ended December 31, 2009.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
- U.S. Food and Drug Administration. (2012). Transmucosal immediate-release fentanyl risk evaluation and mitigation strategy.
- U.S. Food and Drug Administration. (2018). Fentanyl products: Safety information and serious risks of accidental exposure.
